Blueprint Medicines (BPMC) Gross Profit Margin starting from the first quarter 2025 to first quarter 2024, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Blueprint Medicines Corporation  (NASDAQ: BPMC)


Blueprint Medicines's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BPMC Gross Profit Margin (Mar 31 2025)
Q1 		(Dec 31 2024)
Q4 		(Sep 30 2024)
Q3 		(Jun 30 2024)
Q2 		(Mar 31 2024)
Q1
Y / Y Revenue Change 55.45 %
Seq. Revenue Change 2.08 %
Revenue In Millions $149.41
Gross Profit Margin 98.12 %
Gross Profit Margin Total Ranking # 80
Gross Profit In Millions $146.61
Y / Y Gross Profit Change 57.77 %
Seq. Gross Profit Change 5.54 %


Commenting First Quarter 2025 Gross Profit Margin
Blueprint Medicines Corporation Gross Profit grew by 5.54 % in Q1 sequentially to 147 millions, while Revenue increased by 2.08 %, this led to improvement in the company's Gross Profit Margin to 98.12 %, above the Blueprint Medicines Corporation average Gross Profit Margin.


Observing first quarter 2025 results within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 80, from total ranking in the previous quarter at 234.
Learn about Gross Margin
BPMC's Gross Profit Margin first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 11
Overall # 79

Gross Profit Margin Statistics
High Average Low
99.67 % 84.33 % 9.68 %
(Dec 31 2023)   (Mar 31 2022)


BPMC Gross Income Trends • More of BPMC's Profitabilty Ratios • BPMC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
BPMC's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
BPMC's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for BPMC's Competitors
Gross Profit Margin Profit Margin for Blueprint Medicines's Suppliers
Gross Profit Margin Profit Margin for BPMC's Customers

You may also want to know
BPMC's Annual Growth Rates BPMC's Profitability Ratios BPMC's Asset Turnover Ratio BPMC's Dividend Growth
BPMC's Roe BPMC's Valuation Ratios BPMC's Financial Strength Ratios BPMC's Gross Profit Growth
BPMC's Roa BPMC's Inventory Turnover Ratio BPMC's Growth Rates BPMC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2025 MRQ Gross ProfitMar 31 2025 MRQ Revenue
Zai Lab Limited  99.82 %$ 106.292  Millions$ 106.487  Millions
Hyperion Defi inc   99.67 %$ 0.015  Millions$ 0.015  Millions
Ionis Pharmaceuticals Inc   98.89 %$ 130.149  Millions$ 131.612  Millions
Corcept Therapeutics Inc  98.47 %$ 154.811  Millions$ 157.214  Millions
Blueprint Medicines Corporation  98.12 %$ 146.611  Millions$ 149.413  Millions
Siga Technologies Inc  97.76 %$ 6.883  Millions$ 7.041  Millions
Bridgebio Pharma Inc   97.74 %$ 113.994  Millions$ 116.633  Millions
Lexicon Pharmaceuticals Inc   97.62 %$ 1.232  Millions$ 1.262  Millions
Madrigal Pharmaceuticals Inc   96.71 %$ 132.737  Millions$ 137.250  Millions
Gyre Therapeutics Inc   95.95 %$ 21.164  Millions$ 22.058  Millions
Cormedix Inc   95.91 %$ 37.485  Millions$ 39.082  Millions
Karyopharm Therapeutics Inc   95.67 %$ 28.714  Millions$ 30.015  Millions
Adc Therapeutics Sa  94.59 %$ 21.787  Millions$ 23.033  Millions
Travere Therapeutics Inc   94.28 %$ 77.053  Millions$ 81.732  Millions
Optinose Inc   93.58 %$ 25.520  Millions$ 27.270  Millions
Zevra Therapeutics Inc   93.41 %$ 19.056  Millions$ 20.401  Millions
Vanda Pharmaceuticals Inc   92.96 %$ 46.520  Millions$ 50.041  Millions
Axsome Therapeutics Inc   91.94 %$ 111.674  Millions$ 121.463  Millions
Silo Pharma Inc  91.90 %$ 0.017  Millions$ 0.018  Millions
Rigel Pharmaceuticals Inc  91.73 %$ 48.924  Millions$ 53.333  Millions
Bioxcel Therapeutics Inc   91.67 %$ 0.154  Millions$ 0.168  Millions
Acadia Pharmaceuticals Inc   91.65 %$ 223.925  Millions$ 244.317  Millions
Rafael Holdings Inc  91.44 %$ 0.331  Millions$ 0.362  Millions
Regeneron Pharmaceuticals Inc   91.23 %$ 2,763.200  Millions$ 3,028.700  Millions
Amicus Therapeutics inc   91.17 %$ 113.551  Millions$ 124.551  Millions
Kyntra Bio Inc   90.80 %$ 2.487  Millions$ 2.739  Millions
Emmaus Life Sciences Inc   90.65 %$ 2.181  Millions$ 2.406  Millions
Avadel Pharmaceuticals Plc  90.37 %$ 46.934  Millions$ 51.934  Millions
Innoviva Inc   90.16 %$ 73.315  Millions$ 81.315  Millions
Urogen Pharma Ltd   89.96 %$ 17.924  Millions$ 19.924  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.